Rho(D) immune globulin

Results: 65



#Item
31Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality Rebecca M. Turner1*, Myfanwy Lloyd-Jones2, Dilly O. C. Anumba3, Gordon C. S. Smith4

Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality Rebecca M. Turner1*, Myfanwy Lloyd-Jones2, Dilly O. C. Anumba3, Gordon C. S. Smith4

Add to Reading List

Source URL: understandinguncertainty.org

Language: English - Date: 2013-03-08 04:08:41
32Investigation of whether the acute hemolysis associated with Rho(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion r

Investigation of whether the acute hemolysis associated with Rho(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion r

Add to Reading List

Source URL: www.fda.gov.

Language: English
33Immune Globulin Subcutaneous (Human) Vivaglobin

Immune Globulin Subcutaneous (Human) Vivaglobin

Add to Reading List

Source URL: www.fda.gov

Language: English
34Baxter Healthcare Corporation One Baxter Way Westlake Village, California[removed]3000  Cangene Corporation

Baxter Healthcare Corporation One Baxter Way Westlake Village, California[removed]3000 Cangene Corporation

Add to Reading List

Source URL: www.fda.gov

Language: English
35Summary of Basis for Approval - Rho(D) Immune Globulin Intravenous (Human) Rhophylac

Summary of Basis for Approval - Rho(D) Immune Globulin Intravenous (Human) Rhophylac

Add to Reading List

Source URL: www.fda.gov

Language: English
36CSL Behring[removed]Draft Labeling Text 1 2

CSL Behring[removed]Draft Labeling Text 1 2

Add to Reading List

Source URL: www.fda.gov

Language: English
37HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Rhophylac® safely and effectively. See full prescribing information for Rhophylac®.  Rhophylac®

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Rhophylac® safely and effectively. See full prescribing information for Rhophylac®. Rhophylac®

Add to Reading List

Source URL: www.fda.gov

Language: English
38Rho(D) Immune Globulin Intravenous (Human) WinRho® SDF WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis (IVH) leading to death has been reported in patients treated for immune thrombocytopenic purpura (ITP

Rho(D) Immune Globulin Intravenous (Human) WinRho® SDF WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis (IVH) leading to death has been reported in patients treated for immune thrombocytopenic purpura (ITP

Add to Reading List

Source URL: www.fda.gov

Language: English
    39research paper  Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials

    research paper Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials

    Add to Reading List

    Source URL: www.ouhsc.edu

    Language: English - Date: 2011-02-21 15:34:21
    40Microsoft Word - Rh Form  Instructions.doc

    Microsoft Word - Rh Form Instructions.doc

    Add to Reading List

    Source URL: www.cdph.ca.gov

    Language: English - Date: 2014-07-30 12:29:36